SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Abbott India informs about appointment of senior management personnel

16 Apr 2025 Evaluate
In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Abbott India has informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Anushree Kunhambu - Associate Director - New Product Introduction and Therapy Area Strategy effective August 1, 2025. She will be part of the Senior Management team of the Company. The additional details required under the SEBI Listing Regulations read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015, is enclosed as Annexure A. 

The above information is a part of company’s filings submitted to BSE.

Abbott India Share Price

27605.00 943.55 (3.54%)
11-May-2026 11:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1882.50
Dr. Reddys Lab 1290.55
Cipla 1339.80
Zydus Lifesciences 945.35
Lupin 2254.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×